Ani Pharmaceuticals Inc. | Small-cap | Healthcare
$90.61
0.54%
| Ani Pharmaceuticals Stock Comparison:
Ani Pharmaceuticals vs ZoetisAni Pharmaceuticals vs Haleon Plc - ADRAni Pharmaceuticals vs BioCrystAni Pharmaceuticals vs BGMAni Pharmaceuticals vs HarrowAni Pharmaceuticals vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 197.1M
Gross Profit 124.1M 62.95%
Operating Income 14.1M 7.15%
Net Income 15.7M 7.95%
EPS (Diluted) $0.69

Balance Sheet Metrics

Total Assets 1.3B
Total Liabilities 849.0M
Shareholders Equity 443.5M
Debt to Equity 1.91

Cash Flow Metrics

Operating Cash Flow 42.6M
Free Cash Flow 15.1M

Revenue & Profitability Trend

Ani Pharmaceuticals Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i614.4M486.8M316.4M216.1M208.5M
Cost of Goods Sold i250.2M181.5M138.8M100.6M87.2M
Gross Profit i364.2M305.3M177.6M115.5M121.3M
Gross Margin % i59.3%62.7%56.1%53.5%58.2%
Operating Expenses
Research & Development i44.6M34.3M22.3M11.4M16.0M
Selling, General & Administrative i249.6M161.7M124.0M84.3M65.0M
Other Operating Expenses i---780.0K11.3M
Total Operating Expenses i294.2M196.0M146.4M96.4M92.2M
Operating Income i2.2M49.5M-25.7M-28.2M-15.6M
Operating Margin % i0.4%10.2%-8.1%-13.0%-7.5%
Non-Operating Items
Interest Income i-----
Interest Expense i17.6M26.9M28.1M11.9M9.5M
Other Non-Operating Income-6.8M-2.7M-8.9M-16.0M-940.0K
Pre-tax Income i-22.2M19.9M-62.7M-56.1M-26.0M
Income Tax i-3.7M1.1M-14.8M-13.5M-3.4M
Effective Tax Rate % i0.0%5.5%0.0%0.0%0.0%
Net Income i-18.5M18.8M-47.9M-42.6M-22.5M
Net Margin % i-3.0%3.9%-15.1%-19.7%-10.8%
Key Metrics
EBITDA i65.9M109.2M34.6M14.7M28.6M
EPS (Basic) i$-1.04$0.86$-3.05$-3.40$-1.88
EPS (Diluted) i$-1.04$0.85$-3.05$-3.40$-1.88
Basic Shares Outstanding i1931800018001000162600001259600011964000
Diluted Shares Outstanding i1931800018001000162600001259600011964000

Income Statement Trend

Ani Pharmaceuticals Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i144.9M221.1M48.2M100.3M7.9M
Short-term Investments i6.3M----
Accounts Receivable i221.7M162.1M165.4M128.5M95.8M
Inventory i136.8M111.2M105.4M81.7M60.8M
Other Current Assets18.0M17.4M8.4M7.6M5.9M
Total Current Assets i527.7M519.8M344.3M321.8M170.3M
Non-Current Assets
Property, Plant & Equipment i1.2M0000
Goodwill i661.8M265.5M308.1M349.9M195.7M
Intangible Assets i541.8M209.0M251.6M294.1M188.5M
Long-term Investments12.2M12.1M11.4M--
Other Non-Current Assets85.1M90.7M92.7M75.1M57.5M
Total Non-Current Assets i756.0M384.6M415.8M449.8M290.9M
Total Assets i1.3B904.4M760.1M771.6M461.2M
Liabilities
Current Liabilities
Accounts Payable i45.7M36.7M29.3M23.0M11.3M
Short-term Debt i9.2M850.0K850.0K850.0K13.2M
Current Portion of Long-term Debt-----
Other Current Liabilities29.0K12.3M---
Total Current Liabilities i193.7M145.5M99.4M87.5M78.6M
Non-Current Liabilities
Long-term Debt i614.9M284.8M285.7M286.5M172.4M
Deferred Tax Liabilities i-----
Other Non-Current Liabilities25.6M16.5M36.4M38.8M-
Total Non-Current Liabilities i661.5M301.3M322.1M325.3M186.9M
Total Liabilities i855.2M446.8M421.5M412.9M265.5M
Equity
Common Stock i2.0K2.0K1.0K1.0K1.0K
Retained Earnings i-100.3M-80.1M-97.3M-47.8M-5.0M
Treasury Stock i21.0M10.1M5.1M3.1M2.2M
Other Equity-----
Total Shareholders Equity i428.5M457.6M338.5M358.7M195.7M
Key Metrics
Total Debt i624.1M285.7M286.5M287.4M185.7M
Working Capital i334.0M374.3M244.8M234.2M91.8M

Balance Sheet Composition

Ani Pharmaceuticals Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-18.5M18.8M-47.9M-42.6M-22.5M
Depreciation & Amortization i67.7M59.8M59.7M47.3M44.6M
Stock-Based Compensation i29.3M20.7M14.6M10.5M12.9M
Working Capital Changes i-32.8M1.3M-57.9M14.3M-18.3M
Operating Cash Flow i39.0M95.4M-37.6M15.7M9.1M
Investing Activities
Capital Expenditures i-2.7M-8.9M-8.1M92.0K-6.1M
Acquisitions i-401.3M0-33.0K-84.5M0
Investment Purchases i-----
Investment Sales i-----
Investing Cash Flow i-404.0M-8.9M-8.2M-84.4M-6.1M
Financing Activities
Share Repurchases i-11.0M-5.0M-2.0M-890.0K-1.5M
Dividends Paid i-1.6M-1.6M-1.6M-190.0K0
Debt Issuance i641.2M0024.0M15.0M
Debt Repayment i-296.0M-3.0M-3.0M-211.0M-15.5M
Financing Cash Flow i258.5M58.4M-6.6M173.1M5.4M
Free Cash Flow i47.1M100.4M-47.7M-20.3M-53.1M
Net Change in Cash i-106.6M145.0M-52.4M104.5M8.4M

Cash Flow Trend

Ani Pharmaceuticals Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 51.63
Forward P/E 15.82
Price to Book 4.03
Price to Sales 2.54
PEG Ratio -0.14

Profitability Ratios

Profit Margin -1.37%
Operating Margin 7.18%
Return on Equity -2.17%
Return on Assets 1.09%

Financial Health

Current Ratio 2.54
Debt to Equity 136.10
Beta 0.61

Per Share Data

EPS (TTM) $-0.69
Book Value per Share $21.70
Revenue per Share $38.18

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
anip1.9B51.634.03-2.17%-1.37%136.10
Zoetis 65.3B25.3613.1452.77%27.83%137.01
Haleon Plc - ADR 43.4B21.515.469.38%13.81%53.41
BioCryst 1.8B-19.47-4.1618.68%-6.41%-1.75
BGM 1.6B15.004.18-16.52%-26.32%0.22
Harrow 1.4B-78.0228.45-19.03%-4.49%469.08

Financial data is updated regularly. All figures are in the company's reporting currency.